Global Ocular Drug Delivery Technology Market Is Likely To Be Valued At US$ 17.74 Billion In FY 2022
The study on the Global Ocular Drug Delivery Technology Market Insights published by Fact.MR is a comprehensive analysis of the key factors that are likely to determine the growth of Ocular Drug Delivery Technology Market Insights in the upcoming years. Further, the study dives deep to investigate the micro and macro-economic parameters that are expected to influence the global scenario of the Ocular Drug Delivery Technology Market Insights during the forecast period.
The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynami cs of the Ocular Drug Delivery Technology Market Insights in the assessment period.
Request Sample https://www.factmr.com/connectus/sample?flag=S&rep_id=4802
Key Segments Covered in the Ocular Drug Delivery Technology Industry Survey
-
Ocular Drug Delivery Technology by Type :
- Topical Ocular Drug Delivery Technology
- Ocular Drug Delivery Inserts:
- Non-erodible Ocular Drug Delivery Technology
- Erodible Ocular Drug Delivery Technology
- Iontophoresis Ocular Drug Delivery Technology
- Intraocular Implants:
- Biodegradable Ocular Drug Delivery Technology
- Non-biodegradable Ocular Drug Delivery Technology
- In-Situ Gel & Punctal Plugs Ocular Drug Delivery Technology
- Others
-
Ocular Drug Delivery Technology by Formulation :
- Solution based Ocular Drug Delivery Technology
- Suspension based Ocular Drug Delivery Technology
- Emulsion based Ocular Drug Delivery Technology
- Liposomes & Nanoparticles based Ocular Drug Delivery Technology
- Ointment based Ocular Drug Delivery Technology
-
Ocular Drug Delivery Technology by Disease Type :
- Ocular Drug Delivery Technology for Glaucoma
- Ocular Drug Delivery Technology for Diabetic Retinopathy
- Ocular Drug Delivery Technology for Dry Eye Syndrome
- Ocular Drug Delivery Technology for Macular Degeneration
- Ocular Drug Delivery Technology for Diabetic Macular Edema
- Ocular Drug Delivery Technology for Cataract
- Others
-
Ocular Drug Delivery Technology by Region :
- North America Ocular Drug Delivery Technology Market
- Latin America Ocular Drug Delivery Technology Market
- Europe Ocular Drug Delivery Technology Market
- Asia Pacific Ocular Drug Delivery Technology Market
- Middle East & Africa Ocular Drug Delivery Technology Market
Competitive Landscape
Prominent Ocular Drug Delivery Technology providers are reliant on partnerships, collaborations, acquisitions, and new software launches so as to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.
- In Feb 2022, Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, launched ILUVIEN® for non-infectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill).
- In October 2021, Allergan, an AbbVie company, announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of AGN-190584 (pilocarpine HCl ophthalmic solution 1.25%), an investigational novel treatment for presbyopia, at Academy 2021, the annual meeting of the American Academy of Optometry, November 3-6. Presentations included the clinical results for near and intermediate vision, functional near vision, efficacy for post-LASIK patients, and the patient experience.
Key Challenges to Ocular Drug Delivery Technology Industry Expansion
Expensive Cost of Production & Drug-related Side effects to Restrain Market Expansion
Based on the recent analysis, prominent drug manufacturer which hinders the market growth of ocular drug delivery technology which comprises excessive cost and complexities linked with the treatment. Low bioavailability of drugs for conventional ocular therapies is also one of the prominent restraining factors in the ocular drug delivery system market.
Subsequently after the clinical trials, scientists have discovered some side effects of ocular drug delivery technology on the human skin such as irritation, excessive lachrymation, and drug dilution occurring post the treatment which is expected to restrict the market growth over the forecast period.